CHAPTER 34 – Advances in Contrast Agent Development for CT/MRI

[1]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  M. Knopp,et al.  Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. , 2006, Radiology.

[4]  M. Knopp,et al.  Assessment of Utilization and Pharmacovigilance Based on Spontaneous Adverse Event Reporting of Gadopentetate Dimeglumine as a Magnetic Resonance Contrast Agent After 45 Million Administrations and 15 Years of Clinical Use , 2006, Investigative radiology.

[5]  Paul G Tratnyek,et al.  Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting. , 2006, AJNR. American journal of neuroradiology.

[6]  A. Wiethoff,et al.  Initial imaging recommendations for Vasovist angiography , 2006, European radiology.

[7]  J. Heverhagen,et al.  Dosage Determination of Ultrasmall Particles of Iron Oxide for the Delineation of Microvasculature in the Wistar Rat Brain , 2005, Investigative radiology.

[8]  H. Fine,et al.  Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. , 2005, Blood.

[9]  M. Knopp,et al.  Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2004, Radiology.

[10]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[11]  K. Kent,et al.  Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.

[12]  M. Knopp,et al.  Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. , 2003, Radiology.

[13]  D Jacqmin,et al.  Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. , 1998, Radiology.